NCT06370871View on ClinicalTrials.gov

Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 27, 2024

Primary Completion Date

July 3, 2026

Study Completion Date

October 13, 2028

Conditions
Advanced Soft Tissue SarcomaUndifferentiated Pleomorphic Sarcoma (UPS)Myxofibrosarcoma (MFS)
Interventions
DRUG

Brigimadlin

Brigimadlin

DRUG

Ezabenlimab

Ezabenlimab

DRUG

Gemcitabine

Solution for infusion

DRUG

Docetaxel

Solution for infusion

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT06370871 - Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter